|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 October 2017 |
|
Main ID: |
NCT00533351 |
|
Date of registration:
|
19/09/2007 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
Safety and Efficacy of AGN201781 in Neuropathic Pain
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
March 2008 |
|
Target sample size:
|
9 |
|
Recruitment status: |
Terminated |
|
URL:
|
https://clinicaltrials.gov/show/NCT00533351 |
|
Study type:
|
Interventional |
|
Study design:
|
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
Australia
|
Germany
| | | | | | |
|
Contacts
|
|
Name:
|
Medical Director |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Allergan |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosis of postherpetic neuralgia or post-traumatic peripheral neuralgia
- Moderate or severe pain associated with postherpetic neuralgia or post-traumatic
peripheral neuralgia
Exclusion Criteria:
- Women of child-bearing potential
- Any other uncontrolled diseases
Age minimum:
18 Years
Age maximum:
80 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Neuralgia
|
|
Intervention(s)
|
|
Drug: AGN201781
|
|
Drug: placebo
|
|
Primary Outcome(s)
|
|
Change From Baseline in Daily Pain Score at Week 2
[Time Frame: Baseline, Week 2]
|
|
Secondary Outcome(s)
|
|
Change From Baseline in Subject Global Impression of Change Score at Week 2
[Time Frame: Baseline, Week 2]
|
|
Secondary ID(s)
|
|
201781-504
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|